ACADIA PHARMACEUTICALS INC. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
ACADIA PHARMACEUTICALS INC. (ACAD) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $748.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2018-11-06
- 2018-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $748.00K.
- 2018-06-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $1.38M.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2018-09-30 | $748.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.38M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |